TransMedics makes and operates the Organ Care System (OCS) — a portable, "warm perfusion" device that keeps a donor heart, lung, or liver functioning near-physiologically (pumping blood, exchanging oxygen) outside the body, instead of packing it in ice. Cold static storage is the 60-year-old incumbent standard; it limits how far and how long an organ can travel and degrades marginal organs that TransMedics' technology can often keep viable and even assess in transit. The customer is the transplant center; the end beneficiary is the patient on the waitlist.
The company doesn't just sell hardware. Its real business is the National OCS Program (NOP) — a full-service bundle of the OCS console, single-use disposable "organ perfusion sets," and TransMedics' own logistics: an owned fleet of 22 aircraft, ground transport, and on-call clinical specialists who retrieve, perfuse, and deliver the organ. This is closer to a vertically integrated logistics-plus-device company than a pure medtech hardware seller — think "the courier owns the truck, the driver, and the box."
| Segment | Q2 2026 | YoY growth | Notes |
|---|---|---|---|
| Product (OCS consoles + disposables) | $111.2M | +16% | Higher gross margin; liver is the dominant organ by volume |
| Service (NOP logistics, aviation, perfusion staff) | $78.8M | +29% | Lower margin, faster-growing; mix shift is compressing blended gross margin |
The revenue mix is shifting toward the lower-margin service/logistics line as NOP penetration deepens — a structural feature, not a one-off. Heart and lung remain early-stage relative to liver; management is investing heavily to accelerate their adoption (see Section 8).
Revenue is transactional per-case rather than subscription-based — there are no long-term "seat" contracts — but it behaves like recurring revenue in practice because it is tied to an inelastic, non-discretionary event: a life-saving transplant. Once a transplant center adopts NOP for a given organ, switching back to cold storage (or to a smaller competitor without matching logistics infrastructure) is operationally disruptive, which creates real switching costs even without a contractual lock-in.
Customer concentration is low — no single hospital system is likely to be a 10%+ customer given TransMedics serves the majority of active U.S. transplant centers — but there is meaningful geographic concentration in the U.S., which still generates the large majority of revenue. International expansion (Europe, via the PAD Aviation investment closed July 1, 2026) is nascent.
TransMedics has raised NOP service pricing over time and cites pricing actions as a contributor to recent service-revenue growth. However, pricing is also the center of the company's most serious legal and reputational risk: plaintiffs and a prior short-seller report allege customers were effectively forced to buy bundled logistics services to access the device (see Sections 3, 11, and 12).
| Metric | Value |
|---|---|
| FY2025 revenue | $605.5M |
| TTM revenue (through Q2 2026) | ~$636–668M |
| FY2026 guidance | $737M–$757M |
| Market capitalization | ~$3.07B |
| Enterprise value | ~$3.0–3.4B |
| Shares outstanding | ~34.5–34.7M |
| Year | Revenue | YoY growth |
|---|---|---|
| 2021 | $30.3M | — |
| 2022 | $93.5M | +209% |
| 2023 | $241.6M | +159% |
| 2024 | $441.5M | +83% |
| 2025 | $605.5M | +37% |
| 2026E | $737–757M | +22–25% |
The growth curve is decelerating sharply as it should on a much larger base — but 20%+ growth on $600M+ of revenue in a company that is essentially the category creator is still an unusually strong growth profile for a company already at this scale.
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2022 | 70% | ≈−34% | negative |
| 2023 | 64% | ≈−12% | −10.3% (net loss $25.0M) |
| 2024 | 59% | ≈8.5% | 8.0% (net income $35.5M) |
| 2025 | 60% | ≈17.9% | 31.4% (net income $190.3M)* |
| Q1 2026 | 58% | ≈7.6% | 4.2% |
| Q2 2026 | 59.6% | 13.6% (adj.) | 7.7% |
*FY2025 net income was heavily flattered by an $82.8M non-cash tax benefit from releasing a deferred-tax valuation allowance — strip that out and normalized FY2025 net income was closer to $107M, still a strong year but nowhere near the reported 31% net margin implies. This is the single most important "quality of earnings" adjustment in the model.
Gross margin has structurally declined from the 70% product-heavy days of 2022 to the high-50s/low-60s as the lower-margin logistics/service line has grown faster than product. Operating margin swung from deeply negative (funding NOP buildout) to modestly positive by 2024–2025, then compressed again in 2026 — full-year adjusted operating margin guidance was cut from an original ~16% target and 2025's 18.5% down to ~12.5–14%, explicitly because management is reinvesting in OCS Kidney, international expansion, and clinical trials (ENHANCE Heart, DENOVO Lung). This is a deliberate, disclosed reinvestment cycle, not an unexplained deterioration — but it means near-term GAAP earnings will understate steady-state earning power, and it also means the "growth investment" narrative needs to be taken on faith until it shows up in the numbers.
Operating cash flow has turned solidly positive (2024 was the first full year of positive operating cash flow at $48.8M; Q1 2026 alone generated $24.5M). Cash and equivalents stood at roughly $473–488M through mid-2026, with minimal restricted cash. The company is basically debt-light on traditional term debt, but reported interest expense of $7.2M in Q1 2026 tied to finance leases — most notably a large new $334.5M right-of-use asset and $343.8M lease liability for its new Somerville, MA headquarters, signed as a long-term lease in 2025/2026. Total assets reached $1.43B in Q1 2026, materially inflated by this HQ lease.
This lease is the item most likely to be misread by a screener: it pushes "debt-to-equity" ratios up (one data provider showed D/E of 1.75x) and can make the balance sheet look more levered than the company's actual operating debt load, which remains modest. Investors should look through the accounting lease liability to underlying cash obligations rather than treating it as financial leverage in the traditional sense.
TransMedics is unusually capital-intensive for a medtech company because it owns its own aviation fleet (22 aircraft as of Q1 2026, up from 21 a year earlier) rather than outsourcing transport — a deliberate strategic choice to control quality, cost, and reliability of the "cold chain" equivalent for a living organ. This capex is largely growth-related (fleet expansion tracks NOP case growth) rather than pure maintenance capex, but it also means margins are structurally more exposed to fuel costs, pilot labor, and maintenance than a typical device company.
Return on invested capital was reported around 13.5% on a trailing basis by one data provider — respectable but not yet demonstrating the kind of durable, high-teens-plus ROIC that would confirm a wide, mature moat; it is also distorted upward by the one-time tax benefit in the trailing net income figure.
Waleed H. Hassanein, M.D. is the founder, President, and CEO — in the role continuously since founding the company in August 1998, making him one of the longest-tenured founder-CEOs in medtech. He trained as a cardiac surgery researcher (Harvard-affiliated fellowship) rather than coming up through finance, which fits a "product visionary" profile more than a professional operator profile; he has run this business, and essentially only this business, for over 26 years — there is no track record of running a different company at scale to benchmark against.
Under his tenure the company went from a pre-revenue concept to roughly $600M+ in annual revenue and a multi-billion-dollar market cap, which is an unambiguous value-creation record on the top line. The picture is more complicated on execution quality: the stock is down materially from its 2024 all-time highs (north of $150), profitability has been volatile, and the company is now defending a securities fraud lawsuit that directly implicates Hassanein's own public statements about the NOP program (see Section 11).
Hassanein's direct and indirect beneficial ownership was reported around 1.4%–3.8% of shares outstanding depending on the source and date (figures vary because of trust structures and timing), worth roughly $40–80M at various points in 2025–2026 — meaningful in dollar terms but a small percentage of the company. He made an open-market purchase of ~16,875 shares (~$2.0M) in August 2025 at $116–119, which predates the 2026 stock decline and reads as a genuine confidence signal at the time, though the stock has since fallen well below that purchase price. More broadly, aggregate insider selling has continued (one tracker flagged roughly $0.7M of net insider selling in the three months into August 2026) — not alarming in size, but not a strong buying signal either.
2024 CEO total compensation was reported around $8.2M, weighted roughly 92% toward bonus/equity and only 8% base salary — heavily incentive-linked in structure. The annual incentive plan is formulaic against revenue thresholds and capped at 200% of target; it paid out at the maximum in 2024 given the year's 83% revenue growth. Equity mix has shifted from 100% stock options pre-2023 to a 50/50 options/RSU split, a reasonable move toward more balanced long-term alignment. Compensation is tied heavily to revenue growth rather than explicitly to ROIC or free-cash-flow-per-share metrics, which is a governance weakness for a company now entering a phase where capital discipline matters more.
Hassanein also chairs the board as CEO, which is a governance flag (non-independent chair). Average board tenure is reported near 11.8 years — a long-tenured, founder-friendly board. The CFO role has recently turned over (reported as "less than a year" tenure for the current CFO as of late 2025), which adds near-term key-person uncertainty at exactly the moment the company is managing a margin reset and litigation.
A real moat exists here, but it is narrower and more fragile than the bull narrative ("the Amazon of organ transplant") suggests.
The moat is real but not unchallenged. XVIVO Perfusion (Sweden, public), OrganOx (UK, normothermic liver perfusion), and Paragonix Technologies (US, advanced hypothermic transport, arguably the leading player by some market-share counts in preservation broadly) are all active, funded competitors using either perfusion-based or advanced cold-preservation technology in overlapping organ categories. Paragonix in particular has been aggressively expanding partnerships and new product launches. The organ preservation market is described by industry researchers as "less fragmented and highly competitive" rather than a clean monopoly.
Critically, the moat is currently under direct legal attack: the core allegation in the pending securities suit is that TransMedics' apparent market strength partly reflects forced bundling — allegedly compelling customers to buy logistics services to access the device — rather than pure product superiority. A federal judge has allowed that specific claim to proceed past a motion to dismiss (see Section 11). If the underlying business practice is real and is curtailed by litigation, regulatory scrutiny, or customer pushback, part of what looks like a moat today could prove to be a contractual lock-in that erodes once challenged — a meaningfully different risk profile than a pure technology or brand moat.
The addressable opportunity is large and structurally growing: organ transplant waitlists continue to lengthen (total U.S. candidates have grown year over year), donor organ utilization rates remain well below theoretical potential under cold storage, and management's own long-term target is to grow from roughly 441,500-to-600M-plus revenue territory toward 30,000+ annual transplant cases and $2B+ in revenue by 2032 — an ambitious multi-year target that implies the current business is still in the early-to-middle innings of penetration, especially in heart and lung versus liver.
| Multiple | Current | Context |
|---|---|---|
| P/E (TTM, as reported) | ~17–21x | Distorted downward by the one-time $82.8M tax benefit inflating trailing net income |
| P/E (forward) | ~37x | Reflects normalized, tax-adjusted earnings power — the more honest read |
| P/E vs 5-yr median | 5-yr median ~59.5x | Stock is trading well below its own historical multiple range |
| EV/EBITDA | ~23–24x | Not cheap in absolute terms for a company mid-margin-reset |
| EV/Sales | ~4.5–5x | Reasonable for 20%+ revenue growth, but not a screaming bargain |
Using normalized (tax-benefit-excluded) FY2025 net income of roughly $107M, adding back D&A and stock compensation, and subtracting maintenance-level capex (excluding discretionary fleet/HQ growth spend), owner earnings likely land somewhere in the $110–140M range for 2025 — putting the stock at roughly 22–28x owner earnings at the current $3.07B market cap. A conservative DCF using ~15–18% revenue growth tapering toward high-single-digits by year 10, gross margin stabilizing in the high-50s, and a 12% discount rate produces an intrinsic value estimate in a wide band roughly centered in the $80–130 per-share range — consistent with the stock trading near or modestly below fair value, not deeply undervalued, and highly sensitive to the margin-recovery assumption.
TMDX peaked above $150–156 in 2024–2025 and now trades around $80–90, a decline of roughly 40–45% from the 52-week high. The drivers are identifiable and largely fundamental/legal rather than purely sentiment-driven: (1) the securities lawsuit and a January 2025 short-seller report alleging forced bundling and billing practices, which triggered the initial sharp selloff; (2) a court ruling in July 2026 allowing key fraud claims to proceed, reviving the overhang; (3) real margin compression as management reinvests in kidney, international, and clinical programs, cutting adjusted operating margin guidance; and (4) a Q2 2026 earnings miss on adjusted EPS versus consensus. This is not simply "the market panicking over nothing" — each driver reflects a genuine change in the risk or earnings picture.
There is a credible case this is not a value trap — the core technology moat, growth in the underlying NOP case volume, and strong balance sheet are intact — but there is also a credible case that near-22% short interest and persistent litigation risk reflect a real, not phantom, structural problem in how the company has historically monetized its device (the bundling allegations). The margin of safety is moderate, not large: multiples are below historical TMDX averages but not obviously cheap versus peers or on an absolute basis given the litigation and margin uncertainty.
Management has been explicit about a four-pronged strategic plan for 2026 and beyond: (1) accelerating heart and lung transplant adoption in the U.S. through the ENHANCE Heart and DENOVO Lung clinical programs (plus a new Controlled Hypothermic Organ Preservation System, CHOPS, unveiled to support trial control arms); (2) launching the NOP logistics model in Europe via the PAD Aviation investment; (3) advancing OCS Kidney toward clinical launch, which would open a fourth organ category; and (4) continued U.S. NOP density and utilization gains (air mission coverage of NOP cases rose from ~82% to ~86% quarter over quarter, an efficiency improvement).
Early evidence is mixed: logistics/service revenue and gross margin sequentially improved in Q2 2026, and full-year revenue guidance was raised — genuine positive signals. But heart and lung revenue in Q4 2025 (roughly $26M and $1.9M respectively) came in below analyst expectations, indicating those two growth pillars are still early and unproven at scale, and full-year operating margin guidance has been cut twice in 2026, suggesting management's original cost/investment assumptions were too optimistic. Near-term catalysts to watch: OCS Kidney trial data and any FDA regulatory pathway update, ENHANCE Heart/DENOVO Lung trial progress, resolution (or further escalation) of the securities litigation, and evidence that European NOP economics can replicate the U.S. logistics model.
AI is a minor, second-order theme for this business rather than a core value driver in either direction. TransMedics is not meaningfully exposed to AI disruption risk — its core value proposition (a physical perfusion device plus physical logistics for a physical organ) is not substitutable by software or automation in any near-term sense. On the offense side, the company has launched a "digital ecosystem" called NOP ACCESS across major U.S. transplant programs, aimed at improving scheduling, tracking, and case coordination — a data/software layer on top of the physical NOP service, but it is an operational efficiency tool rather than a distinct AI revenue line. TransMedics does not appear to be positioned as an AI-data or AI-infrastructure beneficiary in the way some healthcare data or imaging companies are; its proprietary organ-viability and outcomes data could, in principle, become a valuable training asset for predictive organ-quality algorithms over time, but this is speculative and not yet monetized or quantified by the company.
~$150–170
~$45–55
~$100–115 (12–24 months)
Base-to-bull upside (~15–90%) versus base-to-bear downside (~35–50% from current price) is roughly balanced rather than clearly skewed 2:1 in the investor's favor — this is not a screaming asymmetric bet at today's price. The wide dispersion in analyst targets ($65 to $175 across various snapshots) itself reflects genuine, reasonable disagreement about which scenario is more likely, not just noise.
TransMedics has a genuine, hard-to-replicate technology and regulatory moat, a large and structurally growing addressable market, and a founder-CEO who has demonstrated real execution over 26 years in getting the company from zero to a $600M+ revenue business. The core investment thesis — that warm perfusion structurally displaces cold storage over time — remains intact and is not seriously challenged by any of the research above.
However, three specific, currently unresolved issues keep this out of "Strong Buy" or "Buy" territory: (1) a securities fraud lawsuit with claims a federal judge has allowed to proceed, centered on allegations that directly implicate how much of the company's commercial success reflects customer choice versus alleged coercive bundling; (2) a margin-quality problem — FY2025's headline profitability was substantially a function of a one-time tax benefit, and management has twice cut 2026 operating margin guidance as reinvestment costs ran hotter than planned; and (3) a genuinely high, organized short interest (~22% of float) that reflects real, not manufactured, skepticism from sophisticated market participants.
The trigger points that would move this from "Buy on Weakness" to "Buy": a favorable resolution or manageable settlement of the securities litigation; two consecutive quarters of stabilizing-or-improving operating margin, confirming the reinvestment cycle is on track rather than open-ended; and continued price weakness toward the analyst low-end range ($65–75) without corresponding fundamental deterioration, which would meaningfully improve the risk/reward. Until then, this is a name to size carefully and watch closely rather than accumulate aggressively.